CN104955940A - 用于获得免疫抑制性树突细胞的方法 - Google Patents

用于获得免疫抑制性树突细胞的方法 Download PDF

Info

Publication number
CN104955940A
CN104955940A CN201480003942.3A CN201480003942A CN104955940A CN 104955940 A CN104955940 A CN 104955940A CN 201480003942 A CN201480003942 A CN 201480003942A CN 104955940 A CN104955940 A CN 104955940A
Authority
CN
China
Prior art keywords
monocytes
mammalian subject
dendritic cells
platelets
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480003942.3A
Other languages
English (en)
Chinese (zh)
Inventor
卡斯滕斯·亨佐
京特·鲍尔
贾斯廷·达克沃思
奥德里安·海迪
里查德·埃德尔森
罗伯特·蒂格拉尔
米歇尔·吉拉尔迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRANSIMMUNE AG
Yale University
Original Assignee
TRANSIMMUNE AG
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRANSIMMUNE AG, Yale University filed Critical TRANSIMMUNE AG
Priority to CN202111008277.5A priority Critical patent/CN114410581A/zh
Publication of CN104955940A publication Critical patent/CN104955940A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480003942.3A 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法 Pending CN104955940A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111008277.5A CN114410581A (zh) 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361748550P 2013-01-03 2013-01-03
GB1300052.6 2013-01-03
US61/748,550 2013-01-03
GBGB1300052.6A GB201300052D0 (en) 2013-01-03 2013-01-03 Method for obtaining immuno-suppressive dendritic cells
PCT/EP2014/050012 WO2014106631A1 (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111008277.5A Division CN114410581A (zh) 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法

Publications (1)

Publication Number Publication Date
CN104955940A true CN104955940A (zh) 2015-09-30

Family

ID=47747914

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480003942.3A Pending CN104955940A (zh) 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法
CN202111008277.5A Pending CN114410581A (zh) 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111008277.5A Pending CN114410581A (zh) 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法

Country Status (12)

Country Link
US (2) US20160130552A1 (cg-RX-API-DMAC7.html)
EP (2) EP3719118A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016509474A (cg-RX-API-DMAC7.html)
KR (3) KR20180010345A (cg-RX-API-DMAC7.html)
CN (2) CN104955940A (cg-RX-API-DMAC7.html)
AU (1) AU2014204346B2 (cg-RX-API-DMAC7.html)
CA (1) CA2897113C (cg-RX-API-DMAC7.html)
DK (1) DK2941484T3 (cg-RX-API-DMAC7.html)
ES (1) ES2795927T3 (cg-RX-API-DMAC7.html)
GB (1) GB201300052D0 (cg-RX-API-DMAC7.html)
PL (1) PL2941484T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014106631A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604988A (zh) * 2014-07-03 2017-04-26 特兰西穆内有限公司 用于获得整体活化的单核细胞的方法
CN109701019A (zh) * 2019-01-04 2019-05-03 中国人民解放军第二军医大学 一种新的长链非编码RNA即lnc-Dpf3、其序列、免疫效应及用途
CN118256609A (zh) * 2024-02-06 2024-06-28 湖北文理学院 标志物在监测自身免疫性疾病病程中的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
CN122564053A (zh) 2014-10-31 2026-08-14 麻省理工学院 递送生物分子至免疫细胞
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
GB201513278D0 (en) * 2015-07-03 2015-09-09 Transimmune Ag And Yale University Device and method for obtaining immunostimulatory antigen-presenting cells
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
EP3518942A4 (en) * 2016-09-29 2020-05-27 Hadasit Medical Research Services&Development Ltd. DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
BR112021013193A2 (pt) 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
WO2023283514A1 (en) * 2021-07-06 2023-01-12 Vanderbilt University Fluid shear stress for ex vivo activation of immune effector cells
EP4376860A1 (en) 2021-07-29 2024-06-05 Transimmune AG Methods for selectively reducing immunogenicity in a transplant
US20250375477A1 (en) * 2021-07-29 2025-12-11 Transimmune Ag Selective tolerization - methods of selectively generating tolerogenic dendritic cells
CN121335708A (zh) 2023-05-01 2026-01-13 耶鲁大学 用于疫苗接种的抗原特异性生理性树突状细胞
JP2026516460A (ja) 2023-05-01 2026-05-25 エール・ユニバーシティ 療法用の抗原特異的生理的樹状細胞
WO2026074195A1 (en) 2024-10-05 2026-04-09 Yale University Cytokine loaded activated dendritic cells
WO2026074196A1 (en) 2024-10-05 2026-04-09 Yale University Checkpoint inhibitor loaded activated dendritic cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137365A1 (en) * 2010-04-30 2011-11-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062818A1 (en) 1999-04-20 2000-10-26 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
EP2358739A1 (en) * 2008-11-18 2011-08-24 The University Of Queensland Peptide conjugates for suppressing an immune response, methods of making and uses therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137365A1 (en) * 2010-04-30 2011-11-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAIRD 等: "Generation of immature dendritic cells by modified Extracorporeal photophoresis", 《JOURNAL OF INVESTIGATIVE DERMATOLOGY》 *
RADEK SPISEK 等: "Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease", 《TRANSFUSION》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604988A (zh) * 2014-07-03 2017-04-26 特兰西穆内有限公司 用于获得整体活化的单核细胞的方法
CN109701019A (zh) * 2019-01-04 2019-05-03 中国人民解放军第二军医大学 一种新的长链非编码RNA即lnc-Dpf3、其序列、免疫效应及用途
CN109701019B (zh) * 2019-01-04 2021-07-16 中国人民解放军第二军医大学 一种新的长链非编码RNA即lnc-Dpf3、其序列、免疫效应及用途
CN118256609A (zh) * 2024-02-06 2024-06-28 湖北文理学院 标志物在监测自身免疫性疾病病程中的应用
CN118256609B (zh) * 2024-02-06 2024-08-30 湖北文理学院 Tm9sf1标志物在监测自身免疫性疾病病程中的应用

Also Published As

Publication number Publication date
GB201300052D0 (en) 2013-02-20
AU2014204346B2 (en) 2017-08-31
EP2941484B1 (en) 2020-03-04
JP2018046837A (ja) 2018-03-29
US20160130552A1 (en) 2016-05-12
JP6599958B2 (ja) 2019-10-30
JP2016509474A (ja) 2016-03-31
KR20180010345A (ko) 2018-01-30
HK1210626A1 (en) 2016-04-29
CA2897113C (en) 2024-03-12
PL2941484T3 (pl) 2020-10-05
US20220259556A1 (en) 2022-08-18
JP6804607B2 (ja) 2020-12-23
ES2795927T3 (es) 2020-11-25
KR20150122639A (ko) 2015-11-02
DK2941484T3 (da) 2020-06-02
JP2020018315A (ja) 2020-02-06
EP2941484A1 (en) 2015-11-11
WO2014106631A1 (en) 2014-07-10
CA2897113A1 (en) 2014-07-10
CN114410581A (zh) 2022-04-29
AU2014204346A1 (en) 2015-07-02
KR20200106217A (ko) 2020-09-11
EP3719118A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
US12364755B2 (en) Method for obtaining globally activated monocytes
JP6804607B2 (ja) 免疫抑制樹状細胞を得るための方法
US20220112462A1 (en) Method for obtaining immuno-stimulatory dendritic cells
CA2954090C (en) Method for obtaining globally activated monocytes
HK40068512B (en) Method for obtaining globally activated monocytes
HK40068512A (en) Method for obtaining globally activated monocytes
HK40038738A (en) Method for obtaining immuno-suppressive dendritic cells
HK40042400B (en) Method for obtaining immuno-stimulatory dendritic cells
HK40042400A (en) Method for obtaining immuno-stimulatory dendritic cells
HK1210626B (en) Method for obtaining immuno-suppressive dendritic cells
HK1236835B (en) Globally activated monocytes for use in treating cancer
HK1210625B (en) Method for obtaining immuno-stimulatory dendritic cells

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150930